KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) EBIT (2017 - 2025)

Twist Bioscience (TWST) has disclosed EBIT for 9 consecutive years, with -$32.9 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 5.03% to -$32.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$134.5 million through Dec 2025, up 35.48% year-over-year, with the annual reading at -$136.3 million for FY2025, 38.3% up from the prior year.
  • EBIT for Q4 2025 was -$32.9 million at Twist Bioscience, down from -$29.9 million in the prior quarter.
  • The five-year high for EBIT was -$29.9 million in Q3 2025, with the low at -$88.9 million in Q2 2024.
  • Average EBIT over 5 years is -$48.1 million, with a median of -$45.8 million recorded in 2022.
  • The sharpest move saw EBIT plummeted 70.59% in 2021, then surged 66.13% in 2025.
  • Over 5 years, EBIT stood at -$55.9 million in 2021, then increased by 20.22% to -$44.6 million in 2022, then fell by 5.26% to -$47.0 million in 2023, then rose by 26.25% to -$34.6 million in 2024, then rose by 5.03% to -$32.9 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$32.9 million, -$29.9 million, and -$30.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.